[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.163.94.5. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Quick Uptakes
April 25, 2001

β-Blocker Benefit

Author Affiliations
 

Not Available

Not Available

JAMA. 2001;285(16):2070. doi:10.1001/jama.285.16.2070-JQU10003-4-1

A β-blocker drug slows the progression of artery-clogging plaque in the carotid arteries of healthy people, researchers report in the April 2 issue of Circulation: Journal of the American Heart Association.

The 3-year study by researchers from Sweden found that low dosages (25 mg once daily) of metoprolol CR/XL slows the rate of progression of atherosclerosis by 40% in healthy, symptom-free people who have plaque buildup in their carotid arteries.

The Beta-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS) is a randomized, double-blind, placebo-controlled trial. Study participants were 793 urban, white Swedish people participating in the Malmo Diet and Cancer Study. Participants were randomly assigned to one of four groups: metoprolol CR/XL, fluvastatin, a combination of metoprolol CR/XL and fluvastatin, and placebo. Participants were enrolled beginning in November 1994 for 36-month treatment periods; the study ended in February 1999. The researchers measured the progression of artery wall thickening at 18 months and 36 months.

First Page Preview View Large
First page PDF preview
First page PDF preview
×